Start reading the main story Continue reading the main story Cancer Research UK said once the drug is approved in Europe, patients will be able to discuss treatment options with their doctors. She told BBC: "This is not a cure - you're talking about an extra six months of life. According to the European Medicines Agency, the drug has been recommended for approval in Europe, pending final approval by the European Commission. Kate Law, director of clinical and population research at Cancer Research UK, stated that the treatment is part of a new generation of anti-cancer drugs targeting specific patient genetic makeup. "Looking at these uncertainties, and now the drugs are aimed at cancer patients in the UK, it will be interesting to see the price the manufacturer charges, without too much pressure already on scarce healthcare resources." Doctors said that 132 patients in the US and Australia who were taking the drug vemurafenib gained some additional months of life. Studies in the British Medical Journal found those in the study averaged survival of 16 months, compared to nine months with conventional treatment. Continue reading the main story "We need these targeted drugs, but we have a series of studies still to do to address this issue of resistance," Prior to this, there had been no new drugs for melanoma for over a decade. Vemurafenib targets about half of the patients with advanced melanoma whose tumors express a specific gene mutation. Final offer The main cause of melanoma is considered to be excessive exposure to the sun. "These results tell us that this drug has a very big impact; it changes our treatment of metastatic melanoma." Dr. Anthony Ribas, professor of Hematology/Oncology and researcher at the Anderson Cancer Center at UCLA, said: "This study shows that zelboraf changes the natural history of this disease. This data exceeds my expectations." Elizabeth Woolf, head of the Cancer Information website Help UK at Cancer Research UK, said: "This is an interesting, impressive, but relatively small trial of a promising new generation of melanoma drugs, which is the pride of Cancer Research UK playing a role in its development." "About half of those treated seem to benefit, so it has the potential to help about a quarter of all advanced melanoma patients overall." [Ming You Jing Chun Optimization Room QQ Contact 466401604883847810 product keywords Guarantee 4 on Baidu's first page Eight thousand per year give your site one! Contact number 13422475786] "Everyone was on the drug in the trial, so we cannot tell how great the benefit is compared to those who didn't receive it or received other treatments. Since the drug targets a specific genetic error, only half of all melanoma patients qualify." Around 2000 people die each year in the UK and Wales from melanoma. A new treatment for advanced skin cancer almost doubles survival time, according to an international study. But she said there are still unanswered questions, not just about cost. In the UK, patients will be eligible for the Cancer Drugs Fund, the charity said. "We've seen a large number of patients with durable responses to the drug, and the whole group of patients lived longer. Melanoma, also known as malignant melanoma, is a type of skin cancer that is invasive and dangerous. Vemurafenib (zelboraf) has been recommended for approval in Europe. Cancer Research UK Melanoma is relatively rare, accounting for 10% of all skin cancer cases. Using sunbeds and sunlamps may also increase the risk of developing melanoma. Resistance Kate Law Although it offers hope, she said it is not a cure for cancer, as it eventually becomes resistant to the drug, promoting network marketing in Shantou. "We are somewhere with these targeted drugs, but we have a series of studies still needed to address the issue of resistance, www.bohuicn.com." Melanoma is responsible for most deaths due to skin cancer Malignant melanoma Treatment is a drug therapy for advanced melanoma, approved rapidly last year in the U.S., offering hope for patients with advanced melanoma. Related topic articles: Report confirms lifesaving role colonoscopy Donald barely survived the first round on his way home Skin cancer drug hope raised by study Is McRoe Contact number 13422475786]